Gregory Lo

1.7k total citations · 1 hit paper
12 papers, 1.1k citations indexed

About

Gregory Lo is a scholar working on Oncology, Surgery and Molecular Biology. According to data from OpenAlex, Gregory Lo has authored 12 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Surgery and 4 papers in Molecular Biology. Recurrent topics in Gregory Lo's work include Lung Cancer Research Studies (4 papers), Cancer therapeutics and mechanisms (3 papers) and Neuroendocrine Tumor Research Advances (3 papers). Gregory Lo is often cited by papers focused on Lung Cancer Research Studies (4 papers), Cancer therapeutics and mechanisms (3 papers) and Neuroendocrine Tumor Research Advances (3 papers). Gregory Lo collaborates with scholars based in Canada, United States and Australia. Gregory Lo's co-authors include Theodore E. Warkentin, Christopher Sigouin, Andreas Greinacher, David Juhl, Petra Eichler, Evan W. Warner, Amanda Wong, Alan So, Rahul Aggarwal and Werner J. Struss and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Gregory Lo

12 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin‐induced thrombocytopenia in two clinical settings

2006 675 citations Gregory Lo, David Juhl et al. Journal of Thrombosis and Haemostasis profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gregory Lo Canada	6	820	463	441	388	190	12	1.1k
Darko Antić Serbia	14	91 0.1×	273 0.6×	42 0.1×	297 0.8×	71 0.4×	96	823
Werner Feuerer Germany	9	330 0.4×	185 0.4×	37 0.1×	197 0.5×	147 0.8×	12	837
Bassam Redwan Germany	11	149 0.2×	159 0.3×	44 0.1×	73 0.2×	297 1.6×	42	563
Ivan Budnik Israel	14	107 0.1×	126 0.3×	47 0.1×	491 1.3×	64 0.3×	64	763
Allyson M. Pishko United States	13	197 0.2×	128 0.3×	93 0.2×	189 0.5×	28 0.1×	34	427
Soma Mohammed Australia	19	272 0.3×	246 0.5×	37 0.1×	771 2.0×	97 0.5×	58	1.1k
Annette Poon Canada	15	122 0.1×	122 0.3×	48 0.1×	548 1.4×	84 0.4×	33	812
S. Blattner United States	7	130 0.2×	55 0.1×	43 0.1×	314 0.8×	107 0.6×	8	815
Sam L. Glover United States	5	85 0.1×	162 0.3×	34 0.1×	208 0.5×	41 0.2×	6	417
Christine Biron‐Andréani France	17	118 0.1×	257 0.6×	23 0.1×	586 1.5×	92 0.5×	54	811

Countries citing papers authored by Gregory Lo

Since Specialization

Citations

This map shows the geographic impact of Gregory Lo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory Lo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory Lo more than expected).

Fields of papers citing papers by Gregory Lo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory Lo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory Lo. The network helps show where Gregory Lo may publish in the future.

Co-authorship network of co-authors of Gregory Lo

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory Lo. A scholar is included among the top collaborators of Gregory Lo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory Lo. Gregory Lo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

N., Kim, Sinja Taavitsainen, Nayyer Iqbal, et al.. (2019). Updated results from a randomized phase II study of cabazitaxel (CAB) versus abiraterone (ABI) or enzalutamide (ENZ) in poor prognosis metastatic CRPC.. Journal of Clinical Oncology. 37(15_suppl). 5003–5003. 3 indexed citations

Jiang, Di, Haiyan Jiang, Peter Chung, et al.. (2018). Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer. 17(1). 38–45. 30 indexed citations

Chi, K.N., Sinja Taavitsainen, Nayyer Iqbal, et al.. (2018). A randomized phase II study of cabazitaxel (CAB) vs (ABI) abiraterone or (ENZ) enzalutamide in poor prognosis metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 29. viii271–viii272. 5 indexed citations

Annala, Matti, Werner J. Struss, Evan W. Warner, et al.. (2017). Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate Cancer. European Urology. 72(1). 34–42. 169 indexed citations

Jalal, Shadia I., Philip T. Lavin, Gregory Lo, François Lebel, & Lawrence H. Einhorn. (2017). Carboplatin and Etoposide With or Without Palifosfamide in Untreated Extensive-Stage Small-Cell Lung Cancer: A Multicenter, Adaptive, Randomized Phase III Study (MATISSE). Journal of Clinical Oncology. 35(23). 2619–2623. 23 indexed citations

Sridhar, Srikala S., Shaheena Bashir, Peter Chung, et al.. (2016). Are we systemically under treating cisplatin-eligible patients with muscle invasive bladder cancer (MIBC) who are undergoing bladder preservation by chemoradiotherapy?. Journal of Clinical Oncology. 34(2_suppl). 417–417. 2 indexed citations

Jalal, Shadia I., Lawrence H. Einhorn, Gregory Lo, Philip T. Lavin, & François Lebel. (2015). Results from a randomized study of carboplatin and etoposide (CE) with or without palifosfamide (Pa) in extensive stage small cell lung cancer (ES-SCLC): The MATISSE study.. Journal of Clinical Oncology. 33(15_suppl). 7504–7504. 2 indexed citations

Evans, Tracey L., Joo-Hang Kim, Frances A. Shepherd, et al.. (2013). Cabazitaxel (Cbz) versus topotecan in patients (pts) with small cell lung cancer (SCLC) that has progressed during or after first-line treatment with platinum-based chemotherapy: A randomized phase II study.. Journal of Clinical Oncology. 31(15_suppl). TPS7609–TPS7609. 1 indexed citations

Lo, Gregory, Christopher Sigouin, & Theodore E. Warkentin. (2007). What is the potential for overdiagnosis of heparin‐induced thrombocytopenia?. American Journal of Hematology. 82(12). 1037–1043. 149 indexed citations

10.

Lo, Gregory, David Juhl, Theodore E. Warkentin, et al.. (2006). Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin‐induced thrombocytopenia in two clinical settings. Journal of Thrombosis and Haemostasis. 4(4). 759–765. 675 indexed citations breakdown →

11.

Lo, Gregory & Theodore E. Warkentin. (2005). Towards a Conceptual Framework for Diagnosis of Heparin-Induced Thrombocytopenia (HIT).. Blood. 106(11). 1234–1234. 1 indexed citations

12.

Hu, Cheng, et al.. (2003). Adoptive cellular immunotherapy for non-small cell lung cancer: a pilot study. Cytotherapy. 5(1). 46–54. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact